Stockscreener 앱 받기
14.96
1.32%
-0.20
시장 영업 전:
14.90
-0.06
-0.40%
전일 마감가:
$15.16
열려 있는:
$15.19
하루 거래량:
770.95K
Relative Volume:
0.45
시가총액:
$819.06M
수익:
$15.84M
순이익/손실:
$-308.48M
주가수익비율:
-2.3086
EPS:
-6.48
순현금흐름:
$-153.08M
1주 성능:
-0.53%
1개월 성능:
+1.29%
6개월 성능:
+137.84%
1년 성능:
+176.01%
1일 변동 폭
$14.91
$15.45
1주일 범위
$13.80
$16.20
52주 변동 폭
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
QURE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.96 | 823.42M | 15.84M | -308.48M | -153.08M | -6.48 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com India
uniQure provides regulatory update on AMT-130 for Huntington’s Disease - TipRanks
UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy - marketscreener.com
Transcript : UniQure N.V.Special Call - marketscreener.com
UniQure Provides Regulatory Update On Amt-130 For Huntington'S Disease - marketscreener.com
uniQure aligns with FDA on Huntington’s therapy path By Investing.com - Investing.com Nigeria
uniQure aligns with FDA on Huntington’s therapy path - Investing.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease with FDA Alignment | QURE Stock News - GuruFocus
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - GlobeNewswire
HC Wainwright maintains Buy rating on uniQure stock, $70 target By Investing.com - Investing.com UK
QURE: HC Wainwright & Co. Reiterates Buy Rating for uniQure | QU - GuruFocus
uniQure presents case study of first patient dosed with AMT-260 - TipRanks
uniQure (QURE) Gains Support Following Positive Data from Epilep - GuruFocus
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE S - GuruFocus
uniQure Presents Clinical Case Study of First Patient Dosed - GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) | QURE Stock News - GuruFocus
Revolutionary Gene Therapy Cuts Epilepsy Seizures by 92% in First Patient DataUniQure's Breakthrough - Stock Titan
Down 40% in 2025, Should You Buy the Dip in Marvell Stock? - The Globe and Mail
Long Term Trading Analysis for (QURE) - news.stocktradersdaily.com
uniQure's AMT-130 Gene Therapy Warrants An Upgrade (NASDAQ:QURE) - Seeking Alpha
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - Defense World
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Stock Traders Purchase High Volume of Put Options on uniQure (NASDAQ:QURE) - Defense World
Analysts Set Expectations for uniQure FY2025 Earnings - Defense World
3 Top Genomics Stocks to Add to Your Portfolio in 2025 - Yahoo Finance
Ameriprise Financial Inc. Lowers Position in uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
(QURE) Trading Advice - news.stocktradersdaily.com
Chardan Capital Analysts Cut Earnings Estimates for uniQure - Defense World
Mayfair Gold: Advancing a Modern Vision for Gold Mining - The Globe and Mail
Beyond Medical Technologies Provides Update on 2024 Annual Filings - The Globe and Mail
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? - Yahoo Finance
uniQure (NASDAQ:QURE) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Call Transcript - Insider Monkey
uniQure (NASDAQ:QURE) Receives Buy Rating from Guggenheim - Defense World
uniQure’s (QURE) Buy Rating Reaffirmed at Chardan Capital - Defense World
uniQure N.V. Earnings Call: Progress Amid Challenges - TipRanks
uniQure (QURE) Stock Rating Reaffirmed by Guggenheim | QURE Stoc - GuruFocus
uniQure (QURE) Remains a Strong Buy with Price Target Maintained at $38 | QURE Stock News - GuruFocus
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress - ADVFN
Is uniQure (NASDAQ:QURE) A Risky Investment? - simplywall.st
UniQure: Q1 Earnings Snapshot - New Haven Register
Uniqure NV earnings beat by $0.18, revenue fell short of estimates - Investing.com India
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... - Yahoo Finance
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating R - GuruFocus
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... By GuruFocus - Investing.com Canada
uniQure NV Reports Q1 2025 Earnings: EPS Loss of $0.82 Beats Est - GuruFocus
Transcript : UniQure N.V., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
QURE's Financial Position Strengthened by Recent Capital Raise | - GuruFocus
uniQure (QURE) Reports Lower Q1 Revenue, Advances Huntington's T - GuruFocus
uniQure Q1 2025 Earnings Call Transcript - MarketBeat
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):